AKT1 and non-small cell lung carcinoma: Overall, our data indicate that the interaction of EGFR and STYK1 does not alter the activation of EGFR downstream signaling and that the interplay between STYK1 downregulation and EGFR inhibition in NSCLC cells is independent of the MAPK and PI3K/Akt pathways.